Hologic, Inc. (NASDAQ:HOLX) Sees Significant Increase in Short Interest

Hologic, Inc. (NASDAQ:HOLXGet Free Report) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 5,510,000 shares, an increase of 6.4% from the December 15th total of 5,180,000 shares. Approximately 2.5% of the company’s shares are sold short. Based on an average daily volume of 1,910,000 shares, the days-to-cover ratio is currently 2.9 days.

Hologic Stock Down 0.3 %

Shares of Hologic stock opened at $69.73 on Tuesday. Hologic has a 1 year low of $68.61 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The stock has a market cap of $15.82 billion, a price-to-earnings ratio of 20.94, a PEG ratio of 2.44 and a beta of 0.97. The firm’s 50-day moving average is $74.65 and its two-hundred day moving average is $78.38.

Hologic (NASDAQ:HOLXGet Free Report) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the firm earned $0.89 earnings per share. As a group, research analysts expect that Hologic will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on HOLX. Jefferies Financial Group initiated coverage on shares of Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Raymond James increased their price target on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Leerink Partners dropped their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, Wolfe Research began coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating on the stock. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and an average target price of $88.92.

Get Our Latest Research Report on Hologic

Insider Transactions at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.75% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in HOLX. Wolff Wiese Magana LLC purchased a new position in Hologic in the third quarter valued at about $25,000. General Partner Inc. purchased a new position in shares of Hologic in the 4th quarter worth approximately $26,000. First Horizon Advisors Inc. raised its stake in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares in the last quarter. Sunbelt Securities Inc. purchased a new stake in Hologic during the second quarter valued at approximately $37,000. Finally, Cromwell Holdings LLC boosted its stake in Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 416 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Company Profile

(Get Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Further Reading

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.